Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
about
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancerFrom bench to bedside: immunotherapy for prostate cancerAdvances in preclinical investigation of prostate cancer gene therapy.Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.Cancer immunotherapy: sipuleucel-T and beyond.Exploiting synergy: immune-based combinations in the treatment of prostate cancer.Prostate cancer as a model for tumour immunotherapy.Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.Impact of tumour volume on the potential efficacy of therapeutic vaccines.Viral vector-based therapeutic cancer vaccinesPhase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancerCombining Vaccines with Conventional Therapies for Cancer.Enhancing efficacy of therapeutic vaccinations by combination with other modalities.Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.Role of vaccine therapy in cancer: biology and practiceSipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.Current perspectives in prostate cancer vaccinesPoxviral vectors for cancer immunotherapyCancer vaccines: current directions and perspectives in prostate cancerPSA-based vaccines for the treatment of prostate cancer.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.Cancer vaccines: moving beyond current paradigms.Immunotherapy for metastatic prostate cancerA paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.Paradigm shifts in cancer vaccine therapy.Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapyPromising novel immunotherapies and combinations for prostate cancerRandomized clinical studies of anti-tumor vaccination: state of the art in 2008.Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.Emerging drugs for prostate cancer.Lentiviral vectors for immunization: an inflammatory field.Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.Dendritic-cell vaccination for prostate cancer.Recent developments in prostate cancer biomarker research: therapeutic implications.Recent advances in immunotherapy for the treatment of prostate cancer.PROSTVAC® targeted immunotherapy candidate for prostate cancer.Prostate cancer vaccines in combination with additional treatment modalities.
P2860
Q24684241-B9DF10E0-8861-4E1B-A175-5657C2ABFA12Q26864390-A4E46475-4F6A-494B-9E98-C56770ADD8B2Q33677054-D6A76632-6942-4B53-B5BE-4EB80CA6590BQ33703387-09C6F138-3451-46B2-A141-B25823C07F31Q34074715-600F0382-6746-4398-A77E-594174D9ECC8Q34158070-99FCEBBA-A390-4F42-AFB5-FB9C052E8845Q34687216-E0E8C918-52C2-45AC-8B17-8A49DC6D50D1Q34856875-8CDEA6C5-4B89-4635-9A0A-E7D5DA74C5B1Q34914039-F7726687-5DEA-4D8F-A055-8DB911110D1BQ35027034-2E82BAB3-7953-402A-AAC7-5A0C47799B9EQ35515080-CBC783BA-6D37-4752-98BE-597BFB888A67Q35951653-42611148-7B8C-4252-BE23-95305DB9407CQ36082331-FC56101D-498B-4C53-8616-F66FF4A0AAADQ36113943-3EE7BF77-3F36-4A97-AB03-0CA73A023129Q36254081-9F21D616-B868-484D-A1BF-8564FA7FB607Q36256420-99DE7F0E-092B-4CF4-A8CD-791E8FC96500Q36285594-1A08E5D3-B4C6-46A4-BF8F-0BEF65DC38E4Q36316871-192E5AA5-AF00-4920-9C90-D327CD0ED974Q36317185-88057EC0-A7CB-4E51-B0F6-7F7D3891A8D9Q36350388-1C8D2716-FFEF-42B8-A0D1-7E16BCF745E1Q36368968-2603DA51-3A17-4845-9402-0AD397E5F61FQ36445536-42D6F165-27D6-443F-AC7C-1B99C91F7FB1Q36708792-6B6886FA-F400-4C0E-A954-20480CB4D22EQ36861017-0E2AB33B-1975-4E9A-8EBE-07FAD770173EQ36868126-39487430-F344-4D2D-AF37-AA49AB5955BBQ36949548-EDD0374C-B603-4473-A213-8DC931CC6F5EQ37118188-4D05ABAB-F132-4F13-A95B-914221F26CA1Q37122893-A21B8824-E27C-4C92-964A-0503BA8EC30FQ37193043-6BC50EFF-E8B0-4B85-B7C9-3F3C72103432Q37250456-9B2F58F1-DCBE-4EB9-96A8-2D22BF8A7317Q37354177-BF6D5817-46CD-4188-A2C2-6F41BF500D10Q37443603-EFD62C16-CB13-49D0-8D4E-C9E91D7FB223Q37570555-E76EE3BD-D854-4439-8324-C0C326C13A8FQ37706590-53BAF098-AE17-447F-8B14-1B6737590766Q37732958-695E77A9-6612-4A88-A6DF-B23A6FDC03C6Q37773277-04328535-B7ED-48E8-B23D-BA26D11A976EQ37827186-4E5CA313-9944-4E37-B8A2-CEF47A09D4E4Q37889984-45B8E365-9654-46DC-8CAA-7C20D2AB6247Q38206815-5A3ED397-8947-45C4-819A-39BAB15E2D72Q38212571-B5747D84-E8C1-46C4-BC32-071E2AE93895
P2860
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Antiandrogen, vaccine and comb ...... ne refractory prostate cancer.
@ast
Antiandrogen, vaccine and comb ...... ne refractory prostate cancer.
@en
Antiandrogen, vaccine and comb ...... ne refractory prostate cancer.
@nl
type
label
Antiandrogen, vaccine and comb ...... ne refractory prostate cancer.
@ast
Antiandrogen, vaccine and comb ...... ne refractory prostate cancer.
@en
Antiandrogen, vaccine and comb ...... ne refractory prostate cancer.
@nl
prefLabel
Antiandrogen, vaccine and comb ...... ne refractory prostate cancer.
@ast
Antiandrogen, vaccine and comb ...... ne refractory prostate cancer.
@en
Antiandrogen, vaccine and comb ...... ne refractory prostate cancer.
@nl
P2093
P1476
Antiandrogen, vaccine and comb ...... ne refractory prostate cancer.
@en
P2093
Anne Bastian
Douglas W Grosenbach
James L Gulley
Jeffrey Schlom
Jennifer Marte
Kwong-Yok Tsang
Nushin Todd
Patricia Beetham
Philip M Arlen
Ronald Lieberman
P304
P356
10.1097/01.JU.0000165159.33772.5B
P407
P577
2005-08-01T00:00:00Z